These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33038249)

  • 1. Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell Modulation.
    Luscombe CA; Avihingsanon A; Supparatpinyo K; Gatechompol S; Han WM; Ewart GD; Thomson AS; Miller M; Becker S; Murphy RL
    J Infect Dis; 2021 Jun; 223(11):1914-1922. PubMed ID: 33038249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism.
    Kuhl BD; Cheng V; Donahue DA; Sloan RD; Liang C; Wilkinson J; Wainberg MA
    PLoS One; 2011; 6(11):e27660. PubMed ID: 22110710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.
    Khoury G; Ewart G; Luscombe C; Miller M; Wilkinson J
    Antimicrob Agents Chemother; 2010 Feb; 54(2):835-45. PubMed ID: 19995924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antiviral compound BIT225 inhibits HIV-1 replication in myeloid dendritic cells.
    Khoury G; Ewart G; Luscombe C; Miller M; Wilkinson J
    AIDS Res Ther; 2016; 13():7. PubMed ID: 26858771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection.
    Wilkinson J; Ewart G; Luscombe C; McBride K; Ratanasuwan W; Miller M; Murphy RL
    J Antimicrob Chemother; 2016 Mar; 71(3):731-8. PubMed ID: 26620101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
    Vernazza P; Wang C; Pozniak A; Weil E; Pulik P; Cooper DA; Kaplan R; Lazzarin A; Valdez H; Goodrich J; Mori J; Craig C; Tawadrous M
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):171-9. PubMed ID: 23328090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection.
    Zanni MV; Toribio M; Robbins GK; Burdo TH; Lu MT; Ishai AE; Feldpausch MN; Martin A; Melbourne K; Triant VA; Suchindran S; Lee H; Hoffmann U; Williams KC; Tawakol A; Grinspoon SK
    JAMA Cardiol; 2016 Jul; 1(4):474-80. PubMed ID: 27438325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
    Kabbara WK; Ramadan WH
    J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Vpu Promotes Phagocytosis of Infected CD4
    Cong L; Sugden SM; Leclair P; Lim CJ; Pham TNQ; Cohen ÉA
    mBio; 2021 Aug; 12(4):e0192021. PubMed ID: 34425695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.
    Deeks ED; Perry CM
    Drugs; 2010 Dec; 70(17):2315-38. PubMed ID: 21080746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Kidney Injury After Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (Atripla) Overdose.
    Havenith T; Burger D; Visschers MJ; Schippers J; Oude Lashof A
    Ther Drug Monit; 2017 Apr; 39(2):91-92. PubMed ID: 28230617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
    Rockstroh JK; DeJesus E; Lennox JL; Yazdanpanah Y; Saag MS; Wan H; Rodgers AJ; Walker ML; Miller M; DiNubile MJ; Nguyen BY; Teppler H; Leavitt R; Sklar P;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):77-85. PubMed ID: 23412015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.
    Funderburg NT; Andrade A; Chan ES; Rosenkranz SL; Lu D; Clagett B; Pilch-Cooper HA; Rodriguez B; Feinberg J; Daar E; Mellors J; Kuritzkes D; Jacobson JM; Lederman MM
    PLoS One; 2013; 8(12):e83514. PubMed ID: 24367599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.
    Calza L; Vanino E; Salvadori C; Manfredi R; Colangeli V; Cascavilla A; Di Bari MA; Motta R; Viale P
    HIV Clin Trials; 2014; 15(1):1-13. PubMed ID: 24518210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.
    Ba S; Raugi DN; Smith RA; Sall F; Faye K; Hawes SE; Sow PS; Seydi M; Gottlieb GS;
    Clin Infect Dis; 2018 Oct; 67(10):1588-1594. PubMed ID: 29672676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.